Salute e Benessere
Inventiva reports 2025 First Quarter Financial Information¹
– Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues.
As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024.
The decrease of €28.7 million is primarily due to the net cash used in operating activities related to the planned lanifibranor development program.
Considering its current cost structure and forecasted expenditures, these cash and cash equivalents, combined with the gross proceeds of €115.6 million (net proceeds of €108.5 million) received following the settlement on May 7, 2025 of the second tranche of the previously-announced structured financing of up to €348 million , and taking into account the anticipated receipt of the $10 million (gross proceeds) milestone payment from Chia Tai Tianqing Pharmaceutical Group, Co., LTD (“CTTQ”) within 30 days of the closing of the second tranche of the structured financing mentioned above, and the anticipated completion of the Company's pipeline prioritization plan which is currently being implemented, the Company estimates that its cash and cash equivalents should allow it to fund its operations as currently planned until the end of the third quarter of 2026 .
The Company will need to raise additional funds to achieve its long-term objectives for the development and potential commercialization of lanifibranor through other potential public offerings or private placements and potential strategic options such as business development partnerships, merger and acquisition transactions and/or licensing agreements.
The Company did not recognize revenues for the first quarter of 2025, in line with the first quarter of 2024.
Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH and other diseases with significant unmet medical need. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease.
Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com
Non-audited financial information.
Cf. press release date May 5, 2025
Cf. press release date October 14, 2024
This estimate is based on the Company's current business plan, taking into account the anticipated completion of the Company's pipeline prioritization plan and excludes any potential milestones payable to or by the Company (other than the anticipated milestone payment from CTTQ referenced herein) and any additional expenditures related to other product candidates or resulting from the potential in licensing or acquisition of additional product candidates or technologies, or any associated development the Company may pursue. The Company may have based this estimate on assumptions that are incorrect, and the Company may end up using its resources sooner than anticipated.
Attachment
2321 Rosecrans Avenue. Suite 2200
90245 El Segundo Stati Uniti